England's NHS Stops Prescribing Puberty Blockers to Transgender Minors

The decision comes amid concerns over the lack of evidence for the treatment's safety and effectiveness.

England's National Health Service (NHS) has ceased prescribing puberty blockers to transgender minors, citing a lack of evidence regarding their safety and clinical effectiveness.
The decision has sparked a broad spectrum of reactions, from support by some politicians and detransitioners to condemnation by LGBTQ advocacy groups.
Puberty blockers will still be accessible through clinical research trials and some private clinics, with fewer than 100 young people currently receiving them via the NHS allowed to continue.
Experts and organizations in the U.S. have expressed contrasting views, with major medical associations supporting gender-affirming care as safe and necessary, while others praise the NHS's decision as a step towards protecting children.
The debate over the use of puberty blockers highlights the ongoing global discussion on gender-affirming care for transgender youth, with varying policies and opinions across countries.